(BEAM) Beam Therapeutics - Ratings and Ratios
Base Editing Platform
BEAM EPS (Earnings per Share)
BEAM Revenue
Description: BEAM Beam Therapeutics August 10, 2025
Beam Therapeutics Inc (NASDAQ:BEAM) is a biotechnology company focused on developing gene editing therapies. As a US-based company in the biotechnology sub-industry, BEAMs stock performance is closely tied to advancements in its gene editing technology and the overall sentiment towards the biotech sector.
The companys market capitalization stands at approximately $1.98 billion, indicating a moderate level of market presence. The absence of a Price-to-Earnings (P/E) ratio, both current and forward, suggests that BEAM is not yet profitable, a common characteristic among companies in the biotechnology industry that are often in the development phase. The Return on Equity (RoE) is negative at -44.24%, further indicating that the company is currently operating at a loss.
Key economic drivers for BEAM include the progress of its gene editing pipeline, partnerships or collaborations with other biotech or pharmaceutical companies, and the overall regulatory environment for gene therapies. Investors should monitor clinical trial results, FDA approvals, and any strategic alliances that could impact the companys financials and stock performance.
From a trading perspective, BEAMs stock has shown volatility, with a beta of 2.077 indicating that it is more than twice as volatile as the overall market. This suggests that the stock could be risky but also potentially rewarding for traders willing to take on that risk. Average trading volume is around 2.16 million shares, providing a reasonable level of liquidity.
To evaluate BEAMs potential, investors should focus on key performance indicators (KPIs) such as cash runway, research and development (R&D) expenses as a percentage of total expenses, and the number of ongoing clinical trials. Additionally, news on partnerships, regulatory milestones, and advancements in gene editing technology will be crucial. The companys ability to secure funding, either through equity offerings or partnerships, will also be a critical factor in its ability to continue operations and advance its pipeline.
BEAM Stock Overview
| Market Cap in USD | 2,751m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-02-06 |
BEAM Stock Ratings
| Growth Rating | -55.1% |
| Fundamental | 28.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -10.8% |
| Analyst Rating | 4.41 of 5 |
BEAM Dividends
Currently no dividends paidBEAM Growth Ratios
| Growth Correlation 3m | 88.4% |
| Growth Correlation 12m | -40.2% |
| Growth Correlation 5y | -89.5% |
| CAGR 5y | -18.68% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.26 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.41 |
| Sharpe Ratio 12m | -0.25 |
| Alpha | -29.83 |
| Beta | 2.251 |
| Volatility | 83.94% |
| Current Volume | 1733.7k |
| Average Volume 20d | 2254.6k |
| Stop Loss | 22.1 (-7.1%) |
| Signal | -0.90 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-398.6m TTM) > 0 and > 6% of Revenue (6% = 3.62m TTM) |
| FCFTA -0.26 (>2.0%) and ΔFCFTA -13.40pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 1661 % (prev 241.7%; Δ 1420 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.25 (>3.0%) and CFO -344.8m > Net Income -398.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.75 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (102.0m) change vs 12m ago 23.91% (target <= -2.0% for YES) |
| Gross Margin 72.70% (prev 93.24%; Δ -20.54pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 4.54% (prev 27.95%; Δ -23.41pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -17.11 (EBITDA TTM -396.5m / Interest Expense TTM 24.5m) >= 6 (WARN >= 3) |
Altman Z'' -6.98
| (A) 0.72 = (Total Current Assets 1.18b - Total Current Liabilities 174.1m) / Total Assets 1.39b |
| (B) -1.28 = Retained Earnings (Balance) -1.78b / Total Assets 1.39b |
| warn (B) unusual magnitude: -1.28 — check mapping/units |
| (C) -0.32 = EBIT TTM -418.4m / Avg Total Assets 1.33b |
| (D) -5.16 = Book Value of Equity -1.78b / Total Liabilities 344.3m |
| Total Rating: -6.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 27.97
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -20.26% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.15 = 2.49 |
| 5. Debt/Ebitda 0.32 = 2.42 |
| 6. ROIC - WACC (= -59.27)% = -12.50 |
| 7. RoE -43.15% = -2.50 |
| 8. Rev. Trend -26.33% = -1.97 |
| 9. EPS Trend 0.78% = 0.04 |
What is the price of BEAM shares?
Over the past week, the price has changed by -15.60%, over one month by -0.46%, over three months by +18.11% and over the past year by +5.78%.
Is Beam Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BEAM is around 19.24 USD . This means that BEAM is currently overvalued and has a potential downside of -19.16%.
Is BEAM a buy, sell or hold?
- Strong Buy: 10
- Buy: 4
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BEAM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 45.9 | 92.6% |
| Analysts Target Price | 45.9 | 92.6% |
| ValueRay Target Price | 22.5 | -5.4% |
BEAM Fundamental Data Overview October 17, 2025
P/S = 45.6364
P/B = 2.473
Beta = 2.251
Revenue TTM = 60.3m USD
EBIT TTM = -418.4m USD
EBITDA TTM = -396.5m USD
Long Term Debt = 154.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 12.9m USD (from shortTermDebt, last quarter)
Debt = 154.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -127.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.76b USD (2.75b + Debt 154.8m - CCE 1.15b)
Interest Coverage Ratio = -17.11 (Ebit TTM -418.4m / Interest Expense TTM 24.5m)
FCF Yield = -20.26% (FCF TTM -355.6m / Enterprise Value 1.76b)
FCF Margin = -589.9% (FCF TTM -355.6m / Revenue TTM 60.3m)
Net Margin = -661.3% (Net Income TTM -398.6m / Revenue TTM 60.3m)
Gross Margin = 72.70% ((Revenue TTM 60.3m - Cost of Revenue TTM 16.5m) / Revenue TTM)
Gross Margin QoQ = 34.59% (prev 100.0%)
Tobins Q-Ratio = 1.26 (Enterprise Value 1.76b / Total Assets 1.39b)
Interest Expense / Debt = 7.96% (Interest Expense 12.3m / Debt 154.8m)
Taxrate = -0.0% (0.0 / -102.3m)
NOPAT = -418.4m (EBIT -418.4m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 6.75 (Total Current Assets 1.18b / Total Current Liabilities 174.1m)
Debt / Equity = 0.15 (Debt 154.8m / totalStockholderEquity, last quarter 1.05b)
Debt / EBITDA = 0.32 (negative EBITDA) (Net Debt -127.3m / EBITDA -396.5m)
Debt / FCF = 0.36 (negative FCF - burning cash) (Net Debt -127.3m / FCF TTM -355.6m)
Total Stockholder Equity = 923.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.65% (Net Income -398.6m / Total Assets 1.39b)
RoE = -43.15% (Net Income TTM -398.6m / Total Stockholder Equity 923.7m)
RoCE = -38.80% (EBIT -418.4m / Capital Employed (Equity 923.7m + L.T.Debt 154.8m))
RoIC = -45.30% (negative operating profit) (NOPAT -418.4m / Invested Capital 923.7m)
WACC = 13.97% (E(2.75b)/V(2.91b) * Re(14.31%) + D(154.8m)/V(2.91b) * Rd(7.96%) * (1-Tc(-0.0)))
Discount Rate = 14.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 11.05%
Fair Price DCF = unknown (Cash Flow -355.6m)
EPS Correlation: 0.78 | EPS CAGR: 18.57% | SUE: 1.09 | # QB: 1
Revenue Correlation: -26.33 | Revenue CAGR: -20.30% | SUE: -0.05 | # QB: 0
Additional Sources for BEAM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle